https://adisinsight.springer.com/drugsafety/803892222?error=cookies_not_supported&code=8b348868-090d-463b-9b4e-8972cc309476
Orelabrutinib - AdisInsight
In a single-centre, retrospective study of 10 patients conducted between January 2021 and December 2022, 4 patients [ages and sexes not stated] were described,
adisinsight
https://adisinsight.springer.com/trials/700391613?error=cookies_not_supported&code=e7b26ef5-e9be-4b2c-9e6a-66932dc2b6b3
Orelabrutinib Combined With Anti-CD20 Monoclonal Antibody-CVP Regimen for the Treatment of...
In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with
https://adisinsight.springer.com/trials/700391264?error=cookies_not_supported&code=fcb56962-1fc9-4ee8-a1e8-0dc750ade851
Orelabrutinib in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia: A Prospective,...
1. wAIHA Treatment Regimen: Group A (50mg group): Orelabrutinib 50 mg, orally, once daily. After 4 weeks of treatment, if still transfusion-dependent or
autoimmune hemolytic anemiain the
https://adisinsight.springer.com/drugsafety/803925193?error=cookies_not_supported&code=034833b8-eeae-4c92-bbf6-fed134798714
Orelabrutinib - AdisInsight
Thirty patients with marginal zone B-cell lymphoma received orelabrutinib monotherapy and were evaluated for adverse drug reactions and lack of efficacy. The
adisinsight
https://www.qk.sjtu.edu.cn/jimcp/EN/abstract/article/1673-6087/46547
Recent advances using orelabrutinib in the treatment of mantle cell lymphoma
recent advancesin theusing